Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics

SMi Systems, a company specializing in single molecule imaging and quantification technologies for biomedical research and diagnostics, has disclosed a £6m seed funding round to develop and prove the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research. SMi’s approach will allow diagnostic testing centres to rapidly detect biomarkers and enable earlier patient diagnosis for a range of life-threatening diseases. Alongside this, the technology will significantly accelerate the discovery of new therapeutics by biopharma companies and research institutions. The company has also hired a new Chief Development Officer (CDO) experienced in product commercialization, Dr Michael Risley, to accelerate SMi’s products’ routes to market.

The new platform is underpinned by SMi’s super-resolution optical technology that provides exceptionally high spatial (1.6 nanometre) and temporal (0.5 millisecond) resolution. Coupled with AI, the platform delivers unprecedented quantification of single molecules associated with diseases and those used to develop new therapeutics.

The seed funding included £3.64m from Norcliffe Capital and two Innovate UK grants of £1.89m and £0.42m, which enabled SMi to develop proof-of-principle instruments and prove their application to both infectious disease and cancer biomarker detection.

SMi’s appointment of Dr Michael Risley as CDO will accelerate development of the product to the highest quality standards. Risley, an experienced senior manager, has a track record of developing and delivering complex, regulated in vitro diagnostic (IVD) products. Complementing SMi’s existing comprehensive research expertise, Risley’s leadership and experience will take key elements of the new platform from concept to commercialization conforming to regulatory standards.

“We’ve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but we’re only just scratching the surface of what is possible using our single molecule imaging technology,” says Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi. “With the significant investment we’ve received and the appointment of Michael as CDO, we’re building a strong foundation for us to continue developing our products and accelerate their implementation for a vast range of applications, from disease diagnosis to drug and vaccine discovery. We will soon bring biotech and pharmaceutical scientists, clinicians, and patients the quick answers they need.”

Risley added: “It’s an exciting time to be joining SMi. Its technology will have a significant impact across the life science industry, giving deeper insights to the most complex questions troubling researchers and clinicians. My previous experience of commercializing IVD systems and ensuring they perform to customer expectations leaves me well-prepared for this new challenge — I’m excited to help SMi deliver the full potential of their platform and get it into labs and clinics worldwide.”

For more information on SMi’s new platform and their single molecule imaging technology, please visit https://smisystems.co.uk/

About SMi:

SMi is an innovative life science technology company revolutionizing molecular science with its ground-breaking single-molecule imaging platform. This transformational technology provides unprecedented AI-powered super-resolution imaging to quantify molecules and their intricate interactions with unparalleled accuracy and reliability. SMi’s multi-omic platform offers highly scalable throughput and flexibility, allowing the detection of a broad range of molecule types within a single test. This unique approach facilitates faster, better informed decisions that will drive the future of therapeutic and diagnostic development.

Established with a vision to bring its revolutionary platform to every laboratory bench, SMi delivers world-class results without the need for extensive training or specialized knowledge and will transform biomedical research and diagnostics through speed, quality, and versatility.